ATRC - エイトリキュア （AtriCure Inc.） エイトリキュアATRCのチャート
ATRCの企業情報
| symbol | ATRC |
|---|---|
| 会社名 | AtriCure Inc （エイトリキュア） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 アトリキュア（AtriCure Inc.）は心房細動（Afib）ソリューション会社である。同社は主に心臓組織の外科的アブレーション用に設計されたデバイスと、左心耳を除外するように設計されたシステムを開発、製造、販売している。これには、一定の開放的な手技を受けている患者の永続的かつ永続的な形態のAfibの治療用のIsolator Synergy Ablation Systemを含む、心臓組織の切除用の各種の製品ラインがある。それには、ラジオ周波数アブレーションデバイスおよびcryoICEクリオアブレーションシステム、および左心耳の除外用の製品ラインを含む、心臓組織アブレーションのための2つの主要な製品ラインがある。同社はまた、Lumitip解剖器具および再使用可能な心臓手術（弁）器具のEstechラインを販売している。そのcryoICE凍結手術製品ラインは多様な凍結切除装置を提供する。AtriClip左心房付属器排除システムは、心臓の左心耳（LAA）を閉塞するように設計されている。 エイトリキュアは、米国の医療機器メ―カ―。主な製品は、双極高周波電気メスシステム｢AtriCure RF｣、心房細動治療用チタン製クリップ｢AtriClip｣、電気手術システム｢Synergy｣など。北米、欧州、アジアで製品を販売する。本社は、オハイオ州ウエストチェスタ―。 AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure's Isolator ® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure's AtriClip ® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. |
| 本社所在地 | 7555 Innovation Way Mason OH 45040 USA |
| 代表者氏名 | Scott William Drake スコット・ウィリアム・ドレイク |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 513-755-4100 |
| 設立年月日 | 36800 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2005年 |
| 従業員数 | 570人 |
| url | www.atricure.com |
| nasdaq_url | https://www.nasdaq.com/symbol/atrc |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -8.51300 |
| 終値（lastsale） | 32.53 |
| 時価総額（marketcap） | 1150317499.79 |
| 時価総額 | 時価総額（百万ドル） 1228.918 |
| 売上高 | 売上高（百万ドル） 187.00800 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1244.33 |
| 当期純利益 | 当期純利益（百万ドル） -19.14100 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 AtriCure Inc. revenues increased 14% to $98.8M. Net loss decreased 39% to $10.5M. Revenues reflect United States segment increase of 15% to $79.3M Europe segment increase of 16% to $12.6M. Lower net loss reflects Research and development expenses - Bala decrease of 4% to $16.8M (expense) Interest Income increase of 95% to $199K (income). |
ATRCのテクニカル分析
ATRCのニュース
AtriCure (ATRC) Investor Presentation - Slideshow 2022/08/20 14:55:50 Seeking Alpha
The following slide deck was published by AtriCure, Inc.
AtriCure, Inc. (ATRC) CEO Mike Carrel on Q2 2022 Results - Earnings Call Transcript 2022/08/03 05:08:05 Seeking Alpha
AtriCure, Inc. (NASDAQ:NASDAQ:ATRC) Q2 2022 Earnings Conference Call August 2, 2022 16:30 ET Company Participants Marissa Bych - Investor Relations Mike Carrel - President and Chief…
AtriCure: Q2 Earnings Insights 2022/08/02 21:21:47 Benzinga
AtriCure (NASDAQ: ATRC ) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:01 PM. Here''s what investors need to know about the announcement. Earnings AtriCure missed estimated earnings by 10.34%, reporting an EPS of $-0.32 versus an estimate of $-0.29. Revenue was up $13.15 million from the same period last … Full story available on Benzinga.com
AtriCure GAAP EPS of -$0.32 misses by $0.03, revenue of $84.53M beats by $4.86M 2022/08/02 20:02:05 Seeking Alpha
AtriCure press release (ATRC): Q2 GAAP EPS of -$0.32 misses by $0.03.Revenue of $84.53M (+18.4% Y/Y) beats by $4.86M.
AtriCure Reports Second Quarter 2022 Financial Results 2022/08/02 20:00:00 Wallstreet:Online
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2022 financial results. “We delivered a remarkable second quarter as we continue changing the standard of care for millions of patients globally,” said Michael Carrel,
AtriCure (ATRC) Investor Presentation - Slideshow 2022/08/20 14:55:50 Seeking Alpha
The following slide deck was published by AtriCure, Inc.
AtriCure, Inc. (ATRC) CEO Mike Carrel on Q2 2022 Results - Earnings Call Transcript 2022/08/03 05:08:05 Seeking Alpha
AtriCure, Inc. (NASDAQ:NASDAQ:ATRC) Q2 2022 Earnings Conference Call August 2, 2022 16:30 ET Company Participants Marissa Bych - Investor Relations Mike Carrel - President and Chief…
AtriCure: Q2 Earnings Insights 2022/08/02 21:21:47 Benzinga
AtriCure (NASDAQ: ATRC ) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:01 PM. Here''s what investors need to know about the announcement. Earnings AtriCure missed estimated earnings by 10.34%, reporting an EPS of $-0.32 versus an estimate of $-0.29. Revenue was up $13.15 million from the same period last … Full story available on Benzinga.com
AtriCure GAAP EPS of -$0.32 misses by $0.03, revenue of $84.53M beats by $4.86M 2022/08/02 20:02:05 Seeking Alpha
AtriCure press release (ATRC): Q2 GAAP EPS of -$0.32 misses by $0.03.Revenue of $84.53M (+18.4% Y/Y) beats by $4.86M.
AtriCure Reports Second Quarter 2022 Financial Results 2022/08/02 20:00:00 Wallstreet:Online
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2022 financial results. “We delivered a remarkable second quarter as we continue changing the standard of care for millions of patients globally,” said Michael Carrel,
AtriCure Inc. (NASDAQ: ATRC) Stock Could Be An Option To Consider 2022/06/25 12:30:00 Stocks Register
AtriCure Inc. (NASDAQ:ATRC) shares, rose in value on Friday, 06/24/22, with the stock price up by 3.75% to the previous day’s close as strong demand from buyers drove the stock to $40.92. Actively observing the price movement in the last trading, the stock closed the session at $39.44, falling within a range of $39.08 and … AtriCure Inc. (NASDAQ: ATRC) Stock Could Be An Option To Consider Read More »
AtriCure: 5x Sales For A Series Of Impeding Losses (NASDAQ:ATRC) 2022/06/13 15:44:19 Seeking Alpha
AtriCure presents with numerous inflection points that sit on the distant horizon. Hence, we rate ATRC stock neutral. Click here to see why.
Investment - AtriCure, Inc. Expected to Announce Earnings of -$0.32 Per Share 2022/06/04 12:19:09 Business Mag
Analysts expect AtriCure, Inc. to report earnings per share of for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for…